SynthesisFrontiers in neurology2025
Hearing preservation of post-radiotherapy for acoustic neuroma-a systematic review and meta-analysis.
Synthesis in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Acoustic neuroma (AN), or vestibular schwannoma, is a benign tumor of the eighth cranial nerve. Radiotherapy is a key treatment modality. This systematic review and meta-analysis evaluate post-radiotherapy hearing preservation in patients with AN. Methods: Following PRISMA guidelines, 36 studies published from 2011 to 2020 were identified through searches in PubMed, Cochrane, and Semantic Scholar. Data from 3,903 patients were analyzed using RevMan 5.3. Random-effects models were applied to account for heterogeneity. Results: The pooled hearing preservation rate post-radiotherapy was 55.9%. Gamma Knife and single-session protocols were associated with higher preservation rates. Male sex was linked to a significantly higher risk of hearing loss (RR = 0.83, 95% CI: 0.69-0.99). Tumor control was achieved in the majority of cases (RR = 2.95, 95% CI: 1.94-4.29). Hearing preservation declined with longer follow-up durations. Secondary outcomes included tinnitus, imbalance, and facial nerve dysfunction. Conclusion: Radiotherapy offers favorable tumor control with variable hearing preservation, influenced by treatment modality, sex, and follow-up duration. These findings inform patient counseling and support the need for standardized outcome measures in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.